New FM station coming to Westfield
Westfield Media Specialist Peter Cowles said in late 2023, the Federal Communications Commission opened a one-month filing period for a low power FM station for the first time in a decade. Cowles received permission from Mayor Mike McCabe to apply as a public safety entity and jumped on it, he said. Westfield was one of two applicants out of eight that were selected.
Cowles said Westfield had an original partnership with the Westfield State University student station WSKB, but the students at the university have been wanting it back.
WSFD will be city-owned, with students at Westfield Technical Academy, where the studio is located, as the primary technicians on the station. He said it will also be open to the community at large for programming. The city is licensed with all three businesses, ASCAP, BMI and CESAC to play music. The station will also broadcast all emergency alerts in the city.
On May 12, the Finance committee voted to recommend a transfer of $20,222 from the PEG Undesignated fiscal year 2025 account to the PEG Additional/Capital Equipment Account to purchase equipment for the station to finish off a 300 watt transmitter chain for the emergency Services alarm system. Cowles said they already have the computer, audio board and mics.
Information Technology Manager Lenore Bernashe was able to get additional savings from Westfield Gas & Electric, who will increase the 80-foot tower located at the Water Department by adding 20 feet. Cowles said there are public safety receivers on it now that were put in six to seven years ago, and have a good range.
Cowles said the 100-watt LPV station will reach Springfield and Northampton. 'That's why this site was perfect, and it's backed up on a mountain in Granby,' he said, adding that they will transition over on July 1 when the work is done.
The new station is only one of the changes going on in the studio.
On April 14, the City Council approved an expenditure of $296,915 from the PEG Undesignated Account, which is an enterprise fund, for a Mobile Sprinter Van. The van will cost $80,000 with $217,000 for customization and equipment including a 40-foot mast and camera, and will be used as a mobile television unit, able to cover city meetings and sporting events, and also able to be used as a short-term mobile command post as needed by the Police Department.
Also in the works is a Chapter 74 certification for digital media, formerly called television and radio, as another career technical education program under graphic arts at WTA. 'I think it's a huge advantage for the program,' Cowles said. He said students will be able to run the radio programming and staff the vehicle, with a lot of opportunities to use the equipment and to train.
He said they are presently rewriting the frameworks for the program. The school will be meeting with the Department of Elementary and Secondary Education in the next two weeks for the final word on Chapter 74, and have already toured the television station at WTA and made suggestions. Cowles said all in all they were impressed by the setup at the school. 'I can't believe what you did in such a small space — that's a quote from DESE,' he said.
He said next year when the students return to school, the radio station WSFD will be up and running, and the mobile production unit will be on its way. 'A lot of changes happening all at once,' Cowles said.
Read the original article on MassLive.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
5 days ago
- Business Wire
Lantern Pharma Reports Complete Response in Heavily Pre-Treated Lymphoma Patient with LP-284 in Phase 1 Clinical Trial
DALLAS--(BUSINESS WIRE)-- Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage oncology company leveraging its proprietary RADR® artificial intelligence (AI) platform to systematically transform drug discovery paradigms, today announces that a heavily pretreated patient with aggressive Grade 3 non-germinal center B-cell diffuse large B-cell lymphoma (DLBCL) achieved a complete metabolic response in the ongoing Phase 1 clinical trial of LP-284. This represents the first complete response observed with LP-284 and displays profound clinical activity in one of the most therapeutically challenging hematologic cancers. This extraordinary clinical observation represents a transformative moment for our computationally guided, therapeutic development paradigm Share The RADR®-driven, AI approach enables Lantern to rapidly determine mechanisms of action of any cancer focused molecule, identify biomarker-driven subpopulations and optimize combination strategies for the clinical setting. The 41-year-old patient had previously failed three aggressive treatment regimens over 18 months over the last 15 months. These included: standard R-CHOP/Pola-R-CHP chemotherapy, CAR-T cell therapy (liso-cel), and CD3xCD20 bispecific antibody therapy (glofitamab). Following enrollment in April 2025, the patient achieved complete metabolic response with non-avid lesions after completing just two 28-day cycles of LP-284 administered on days one, eight, and 15. This remarkable clinical outcome supports LP-284's synthetic lethal mechanism and is an initial step towards a potential new paradigm for treating refractory aggressive lymphomas and B-cell malignancies. Paradigm-Shifting Observation of Complete Response in Therapeutically Exhausted Patient 'This extraordinary clinical observation represents a transformative moment for our computationally guided, therapeutic development paradigm,' said Panna Sharma, President and CEO of Lantern Pharma. 'Our RADR® platform's systematic analysis of molecular vulnerabilities enabled us to rapidly advance LP-284 from computational concept to a clinical milestone in a patient in under three years at approximately $3 million — demonstrating how AI-driven precision has the promise to fundamentally reshape pharmaceutical innovation. This complete metabolic response in a patient who had exhausted all conventional therapeutic options strongly supports our strategic thesis that computational approaches can unlock previously inaccessible therapeutic opportunities.' LP-284, a computationally optimized next-generation acylfulvene, was systematically developed with guidance from Lantern's RADR® platform to exploit synthetic lethal interactions in cancer cells harboring specific DNA damage repair deficiencies. The compound represents a fundamentally different therapeutic strategy with the potential to preferentially target malignant cells while preserving healthy tissue function — a precision approach aimed at delivering transformative clinical benefit for patients who have failed multiple prior treatment modalities. Potential to Address a Critical Therapeutic Void in Refractory DLBCL This patient's clinical journey exemplifies the devastating trajectory of aggressive DLBCL in the refractory setting. Despite achieving an initial complete metabolic response with CAR-T therapy (liso-cel) at day 30, the patient experienced disease progression by day 90. Subsequent treatment with the CD3xCD20 bispecific antibody glofitamab resulted in progressive disease with multifocal new lesions. At study entry on the LP-284-Phase 1 trial in April 2025, the patient presented with extensive multifocal bony lesions across thoracic and lumbar spine locations and hips — representing an extremely challenging clinical scenario. The achievement of complete metabolic response with non-avid lesions following just two cycles of LP-284 therapy represents a potential future paradigm-shifting alternative for treating therapeutically exhausted DLBCL patients. This encouraging outcome underscores LP-284's potential to address critical gaps in the therapeutic armamentarium for patients who have failed both conventional and cutting-edge immunotherapeutic approaches. Advancing Strategic Clinical Development and Global Expansion The complete metabolic response achievement positions LP-284 for accelerated development pathways and strengthens Lantern's strategic position in the competitive hematologic oncology landscape. This clinical milestone provides important confirmation of the company's systematic approach to therapeutic development and creates additional opportunities for international partnership expansion and collaborative research initiatives. Lantern's ongoing Phase 1 dose-escalation study (NCT06132503) is designed to evaluate LP-284's safety profile, optimal dosing parameters, and preliminary efficacy signals across multiple aggressive lymphoma subtypes. The trial's systematic design enables precise evaluation of LP-284's therapeutic potential across genetically defined patient populations, with a current focus on aggressive NHL subtypes including mantle cell lymphoma and high-grade B-cell lymphomas. LP-284's multiple FDA Orphan Drug Designations position the compound for potential expedited regulatory pathways and enhanced market exclusivity frameworks. Transforming Global Oncology Through Computational Precision This clinical development provides important confirmation of the transformative potential of Lantern's RADR® platform, which leverages over 200 billion oncology-focused data points and 200+ machine learning algorithms to assist in systematically identifying and optimizing therapeutic opportunities. The platform's computational efficiency enabled Lantern to rapidly advance the LP-284's program into the clinic in under three years at a cost of approximately $3 million — representing striking development efficiency compared to traditional pharmaceutical paradigms. The complete metabolic response achievement positions LP-284 to seek a future role within a global blood cancer market focused on B-cell cancer that is estimated at $4 billion annually, with DLBCL representing the largest aggressive lymphoma subtype affecting approximately 200,000 patients globally each year. The critical unmet need in refractory/relapsed settings represents a substantial commercial opportunity for innovative therapeutic approaches that can deliver meaningful clinical benefit to therapeutically exhausted patient populations. Next Steps and Future Development Lantern plans to continue enrollment in the Phase 1 trial while closely monitoring the responding patient and other potential future patients for durability of response and efficacy signals. The company anticipates providing additional clinical updates as the trial progresses and more patients reach evaluable timepoints. The complete response achievement positions LP-284 for potential accelerated development pathways and creates opportunities for strategic partnerships as Lantern advances its synthetic lethal portfolio toward later-stage clinical trials. About LP-284 LP-284 is an investigational next-generation acylfulvene designed to exploit synthetic lethal interactions in cancer cells with DNA damage repair deficiencies. Developed with guidance from Lantern's AI platform RADR®, LP-284 represents a novel therapeutic approach with potential to address critical gaps in the treatment of relapsed or refractory non-Hodgkin's lymphoma and other hematologic malignancies. The compound is currently being evaluated in a Phase 1 clinical trial (NCT06132503) to determine its safety profile, optimal dosing, and potential activity in patients with aggressive NHL subtypes who have failed standard therapies. LP-284 has received multiple Orphan Drug Designations from the U.S. Food and Drug Administration, including designations for mantle cell lymphoma and high-grade B-cell lymphomas, recognizing its potential to address significant unmet medical needs in rare cancer populations. About Lantern Pharma Lantern Pharma (NASDAQ: LTRN) is an AI-driven biotechnology company focused on accelerating and optimizing the discovery, development, and commercialization of cancer therapies. Its proprietary RADR® platform leverages artificial intelligence and machine learning with the aim of uncovering novel therapeutic opportunities, accelerating drug development timelines, and improving patient outcomes. The company's approach combines advanced computational biology with traditional pharmaceutical development to transform how cancer drugs are discovered and developed. For more information, visit: - Website: ( - LinkedIn: - X: @lanternpharma ( Forward-Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements include, among other things, statements relating to: future events or our future financial performance; the potential advantages of our RADR ® platform in identifying drug candidates and patient populations that are likely to respond to a drug candidate; our strategic plans to advance the development of our drug candidates and antibody drug conjugate (ADC) development program; estimates regarding the development timing for our drug candidates and ADC development program; expectations and estimates regarding clinical trial timing and patient enrollment; our research and development efforts of our internal drug discovery programs and the utilization of our RADR ® platform to streamline the drug development process; our intention to leverage artificial intelligence, machine learning and genomic data to streamline and transform the pace, risk and cost of oncology drug discovery and development and to identify patient populations that would likely respond to a drug candidate; estimates regarding patient populations, potential markets and potential market sizes; sales estimates for our drug candidates and our plans to discover and develop drug candidates and to maximize their commercial potential by advancing such drug candidates ourselves or in collaboration with others. Any statements that are not statements of historical fact (including, without limitation, statements that use words such as "anticipate," "believe," "contemplate," "could," "estimate," "expect," "intend," "seek," "may," "might," "plan," "potential," "predict," "project," "target," "model," "objective," "aim," "upcoming," "should," "will," "would," or the negative of these words or other similar expressions) should be considered forward-looking statements. There are a number of important factors that could cause our actual results to differ materially from those indicated by the forward-looking statements, such as (i) the risk that we may not be able to secure sufficient future funding when needed and as required to advance and support our existing and planned clinical trials and operations, (ii) the risk that observations in preclinical studies and early or preliminary observations in clinical studies do not ensure that later observations, studies and development will be consistent or successful, (iii) the risk that our research and the research of our collaborators may not be successful, (iv) the risk that we may not be successful in licensing potential candidates or in completing potential partnerships and collaborations, (v) the risk that none of our product candidates has received FDA marketing approval, and we may not be able to successfully initiate, conduct, or conclude clinical testing for or obtain marketing approval for our product candidates, (vi) the risk that no drug product based on our proprietary RADR ® AI platform has received FDA marketing approval or otherwise been incorporated into a commercial product, and (vii) those other factors set forth in the Risk Factors section in our Annual Report on Form 10-K for the year ended December 31, 2024, filed with the Securities and Exchange Commission on March 27, 2025. You may access our Annual Report on Form 10-K for the year ended December 31, 2024, under the investor SEC filings tab of our website at ( or on the SEC's website at ( Given these risks and uncertainties, we can give no assurances that our forward-looking statements will prove to be accurate, or that any other results or events projected or contemplated by our forward-looking statements will in fact occur, and we caution investors not to place undue reliance on these statements. All forward-looking statements in this press release represent our judgment as of the date hereof, and, except as otherwise required by law, we disclaim any obligation to update any forward-looking statements to conform the statement to actual results or changes in our expectations.
Yahoo
19-07-2025
- Yahoo
A Closer Look At Public Service Enterprise Group Incorporated's (NYSE:PEG) Impressive ROE
While some investors are already well versed in financial metrics (hat tip), this article is for those who would like to learn about Return On Equity (ROE) and why it is important. To keep the lesson grounded in practicality, we'll use ROE to better understand Public Service Enterprise Group Incorporated (NYSE:PEG). Return on equity or ROE is a key measure used to assess how efficiently a company's management is utilizing the company's capital. In other words, it is a profitability ratio which measures the rate of return on the capital provided by the company's shareholders. AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early. How Is ROE Calculated? ROE can be calculated by using the formula: Return on Equity = Net Profit (from continuing operations) ÷ Shareholders' Equity So, based on the above formula, the ROE for Public Service Enterprise Group is: 11% = US$1.8b ÷ US$16b (Based on the trailing twelve months to March 2025). The 'return' is the profit over the last twelve months. One way to conceptualize this is that for each $1 of shareholders' capital it has, the company made $0.11 in profit. View our latest analysis for Public Service Enterprise Group Does Public Service Enterprise Group Have A Good Return On Equity? Arguably the easiest way to assess company's ROE is to compare it with the average in its industry. However, this method is only useful as a rough check, because companies do differ quite a bit within the same industry classification. As is clear from the image below, Public Service Enterprise Group has a better ROE than the average (8.9%) in the Integrated Utilities industry. That's clearly a positive. Bear in mind, a high ROE doesn't always mean superior financial performance. A higher proportion of debt in a company's capital structure may also result in a high ROE, where the high debt levels could be a huge risk . To know the 2 risks we have identified for Public Service Enterprise Group visit our risks dashboard for free. The Importance Of Debt To Return On Equity Companies usually need to invest money to grow their profits. The cash for investment can come from prior year profits (retained earnings), issuing new shares, or borrowing. In the first two cases, the ROE will capture this use of capital to grow. In the latter case, the debt used for growth will improve returns, but won't affect the total equity. Thus the use of debt can improve ROE, albeit along with extra risk in the case of stormy weather, metaphorically speaking. Combining Public Service Enterprise Group's Debt And Its 11% Return On Equity Public Service Enterprise Group does use a high amount of debt to increase returns. It has a debt to equity ratio of 1.43. With a fairly low ROE, and significant use of debt, it's hard to get excited about this business at the moment. Debt does bring extra risk, so it's only really worthwhile when a company generates some decent returns from it. Summary Return on equity is one way we can compare its business quality of different companies. A company that can achieve a high return on equity without debt could be considered a high quality business. If two companies have the same ROE, then I would generally prefer the one with less debt. Having said that, while ROE is a useful indicator of business quality, you'll have to look at a whole range of factors to determine the right price to buy a stock. The rate at which profits are likely to grow, relative to the expectations of profit growth reflected in the current price, must be considered, too. So you might want to check this FREE visualization of analyst forecasts for the company. Of course Public Service Enterprise Group may not be the best stock to buy. So you may wish to see this free collection of other companies that have high ROE and low debt. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. 擷取數據時發生錯誤 登入存取你的投資組合 擷取數據時發生錯誤 擷取數據時發生錯誤 擷取數據時發生錯誤 擷取數據時發生錯誤
Business Wire
18-07-2025
- Business Wire
Delek US Holdings to Host Second Quarter 2025 Conference Call on August 6 th
BRENTWOOD, Tenn.--(BUSINESS WIRE)--Delek US Holdings, Inc. (NYSE: DK) ('Delek US') today announced that the Company intends to issue a press release summarizing second quarter 2025 results before the U.S. stock market opens on Wednesday, August 6, 2025. A conference call to discuss these results is scheduled to begin at 10:00 a.m. CT (11:00 a.m. ET) on Wednesday, August 6, 2025. The live broadcast of this conference call will be available online by going to and clicking on the investor relations section of the website. The online replay will be available on the website for 90 days. About Delek US Holdings, Inc. Delek US Holdings, Inc. is a diversified downstream energy company with assets in petroleum refining, logistics, pipelines, and renewable fuels. The refining assets consist primarily of refineries operated in Tyler and Big Spring, Texas, El Dorado, Arkansas and Krotz Springs, Louisiana with a combined nameplate crude throughput capacity of 302,000 barrels per day. The logistics operations include Delek Logistics Partners, LP (NYSE: DKL). Delek Logistics Partners, LP is a growth-oriented master limited partnership focused on owning and operating midstream energy infrastructure assets. Delek US Holdings, Inc. and its subsidiaries owned approximately 63.6% (including the general partner interest) of Delek Logistics Partners, LP as of February 18, 2025. Information about Delek US Holdings, Inc. can be found on its website ( investor relations webpage ( and news webpage (
